1. First observation of inhibitor development against efmoroctocog alfa in France.
- Author
-
Chamouni, Pierre, Barbay, Virginie, Billoir, Paul, Le Cam-Duchez, Véronique, Malassigne, Céline, Massy, Nathalie, and Königs, Christoph
- Subjects
- *
BLOOD coagulation factor VIII , *EMICIZUMAB , *HEMOPHILIA , *HEMORRHAGE , *CHIMERIC proteins - Abstract
In patients with severe haemophilia receiving clotting factor concentrates, the risk of immunisation against their usual treatment is still patent and feared. New haemophilia drug treatments with an extended half-life have become available over the past few years. The risk of inhibitor development to these new treatments is unclear. We report the case of a 51-year-old man with severe haemophilia A, who was previously treated with no history of inhibitor development. Soon after a switch in his treatment to efmoroctocog alfa he developed an inhibitor against this recombinant Fc fusion extended half-life FVIII (rFc-FVIII) product. The patient was on an on-demand treatment regimen and was treated for mucosal bleeding. The inhibitor was characterised as type I, with classical epitope mapping. The spontaneous evolution of this inhibitor was favourable, but an anamnestic response led to a switch in his treatment to emicizumab. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF